Asterias Biotherapeutics Reports Fourth Quarter And Full Year 2014 Financial And Operating Results

"We are continuing to advance these programs and expect multiple, meaningful clinical milestones over the next 24 months. Last week, Asterias achieved another significant milestone with our AST-OPC1 program, announcing commencement of patient enrollment for the dose-escalation Phase 1/2a clinical trial in complete cervical spinal cord injury.

http://ift.tt/18bUum3